Astellas expecting strong Xtandi growth as currency boosts 1Q
This article was originally published in Scrip
Executive Summary
Following its launch in the US last September, Astellas is forecasting rapid growth for Xtandi (enzalutamide) in what is set to be the prostate cancer drug's largest single market. Although sales were a modest at $82m (JPY8.5bn) in the Japanese firm's fiscal first quarter, they are expected to top $400m (JPY40.0bn) for the full year ending next 31 March as promotional efforts gather steam.